case_images: PMC11324273_01
case_images: Oncology treatment timeline of the patient is shown.
case_images: cro-2024-0017-0001-540354_F01.jpg
case_images: PMC11324273_01_cro-2024-0017-0001-540354_F01.jpg
case_images: F1
case_images: The patient's oncology treatment timeline is shown in Figure 1.
case_images: The treatment timeline of recurrent urothelial carcinoma, hyperglycemia, FN, and AKI are shown. a The patient's body temperature as a dashed line is shown. Arrows show the date the EV was administered. The squares show when and what antibiotic is administered. Filgrastim is also shown as a square. b. The patient's neutrophil count as a dotted line is shown. c The renal function is shown. Creatinine concentration in the blood is shown as a dashed line, and the urine output per hour is shown as gray bar. The duration of continuous hemodiafiltration and CVII are shown as squares on top and bottom of the graph. d The blood glucose level change and administered insulin therapy are shown. The solid line shows the early morning fasting blood glucose level is shown as a solid line, and the totally administered daily dose of insulin are shown as the white bars. TAZ/PIPC, tazobactam/piperacillin; MEPM, meropenem; VCM, vancomycin; MCFG, micafungin.
case_images: cro-2024-0017-0001-540354_F02.jpg
case_images: PMC11324273_01_cro-2024-0017-0001-540354_F02.jpg
case_images: F2
case_images: The treatment timeline for FN is presented in Figure 2. The blood glucose level gradually fell and the total insulin dose was reduced to 30-60 units/day after CHDF treatment. The clinical course is shown in Figure 2.